{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-103126","form_type":"8-K","ticker":"CADL","cik":"0001841387","company_name":"Candel Therapeutics, Inc.","filed_at":"2026-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.494413+00:00","generated_at":"2026-05-15T13:49:55.383707+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Candel reports Q4 2025 net loss of $29.5M; cash $119.7M; plans BLA for aglatimagene in Q4 2026","bullets":["Net loss Q4 2025: $29.5M vs $14.1M Q4 2024; full year net loss $38.2M vs $55.2M (2024).","Cash $119.7M at Dec 31, 2025; plus $93.5M net from Feb 2026 offering; runway into Q1 2028.","Entered $130M term loan with Trinity Capital; $50M drawn; $100M royalty deal with RTW contingent on FDA approval.","Plan to initiate pivotal phase 3 trial of aglatimagene in NSCLC in Q2 2026; BLA submission for prostate cancer in Q4 2026.","FDA cleared IND for linoserpaturev in recurrent high-grade glioma; mature OS data expected Q4 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-103126","json":"https://secwatch.observer/filing/0001193125-26-103126.json","markdown":"https://secwatch.observer/filing/0001193125-26-103126.md","text":"https://secwatch.observer/filing/0001193125-26-103126.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841387/000119312526103126/0001193125-26-103126-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841387/000119312526103126/cadl-20260312.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T13:49:55.383707+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"14a2bf8ac886421ab2d974fc727da2e695005486","claim":"Candel Therapeutics, Inc. reported financial results for the quarter and year ended December 31, 2025.","evidence_excerpt":"On March 12, 2026, Candel Therapeutics, Inc. announced its financial results for the quarter and year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1841387/000119312526103126/0001193125-26-103126-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}